Baculovirus Particles (BVPs) for Antibody Polyreactivity Screening
Polyreactivity, defined as non-specific binding of an antibody to structurally unrelated targets, is a well-documented liability in therapeutic antibody development. Elevated polyreactivity has been associated with faster in vivo clearance of therapeutic antibody candidates in preclinical studies, and is commonly assessed at the lead-selection stage as one input to a broader developability evaluation.
Curia supplies purified baculovirus particles (BVPs) as a reagent for use as the coating antigen in an ELISA-based polyreactivity assay. Test antibodies that produce elevated absorbance against immobilized BVPs, relative to defined controls, are flagged for further evaluation and can be triaged, engineered, or advanced with additional monitoring.
Product Specifications
- Format: purified baculovirus particles supplied in phosphate-buffered saline (PBS)
- Concentration: 3.0-3.5 mg/mL
- Pack size: 50 uL with a 1:100 dilution
- Storage: -80 °C
Background
The reagent was originally offered by LakePharma, which was acquired by Curia in 2021 and has remained the gold standard for antibody polyreactivity testing. It has been referenced in peer-reviewed studies covering monoclonal, bispecific and single-domain (VHH-Fc) antibody formats, including in a 2024 study that used BVP-ELISA data as a training input for protein language model-based polyreactivity prediction.
Relevant Publications
- Van Regenmortel, M.H., Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit, 2014. 27(11): p. 627-39.
- Hotzel, I., et al., A strategy for risk mitigation of antibodies with fast clearance. MAbs, 2012. 4(6): p. 753-60.
- Xu, Y., et al., Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel, 2013. 26(10): p. 663-70.
Companion Services
For customers who prefer to outsource the assay, Curia provides BVP-ELISA screening as a standalone service or as part of a developability assessment package that also includes in silico sequence liability analysis, aggregation, purity, charge variant, thermostability, post-translational modification analyses and advanced immunogenicity testing. Contact business development for current scope, turnaround, and pricing.
For orders, quotes, or scientific inquiries, contact Curia today.
